[The effect of calcium channel blocker lercanidipine on lowgrade inflammation parameters in essential hypertension patients]

Full Abstract

INTRODUCTION:
Oxidative stress (OS), inflammation and insulin resistance are among the mechanisms that have been recently implicated in pathogenesis of essential hypertension (EH). Peripheral polymorphonuclear leukocytes (PMNLs) are primed in EH patients, releasing uncontrolled superoxide anion contributing to OS and chronic low-grade inflammation in these patients. PMNL priming correlates with insulin resistance and with PMNL intracellular calcium ([Ca2+]i). Recent studies have attributed additional anti-oxidative characteristics to the anti-hypertensive drug Lercanidipine (Vasodip), a third generation calcium-channel blocker.

AIM:
To evaluate possible novel effects of two months of Lercanidipine treatment on systemic and PMNL-related inflammation and on insulin resistance in EH patients.

METHODS:
Fifteen non-smoking EH patients with untreated mild to moderate high blood pressure (BP) and age- and gender-matched healthy controls (HC) were included in the study. Low-grade inflammation was expressed by PMNL counts and apoptosis, by plasma fibrinogen, CRP and albumin (as a negative acute phase reactant) levels. Fasting serum insulin levels served as a marker of insulin resistance.

RESULTS:
Inflammation parameters and insulin levels were higher in EH compared to HC. PMNL counts, fibrinogen and insulin levels positively correlated with mean arterial blood pressure values. Two months of Lercanidipine treatment showed a significant decrease in BP, PMNL counts and apoptosis, CRP and serum insulin levels and a significant increase in serum albumin levels.

CONCLUSION:
The authors imply that the low-grade systemic inflammation and insulin resistance detected in EH patients may be attenuated by the use of Lercanidipine, adding new unknown anti-inflammatory properties to this calcium channel blocker.

Learn Faster Today Improve your study skills

Author information

Author/s: Shurtz-Swirski, Revital (R); Farah, Raymond (R); Sela, Shifra (S); Shapiro, Galina (G); Klempef, Regina (R); Snitkovski, Tamara (T); Kristal, Batya (B);

Affiliation: Eliachar Research Laboratory, Technion, Haifa, Israel. revital.shurtz-swirski(-atsign-)naharia.health.gov.il

Journal and publication information

Publication Type: English Abstract; Journal Article

Journal: Harefuah (Harefuah), published in Israel. (Language: heb)

Reference: 2006-Dec; vol 145 (issue 12) : pp 895-9, 942

Dates: Created 2007/01/15; Completed 2007/03/22;

PMID: 17220028, status: MEDLINE (last retrieval date: 12/26/2008)

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article (including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Adult
Aged
Antihypertensive Agents - therapeutic use
Blood Pressure - drug effects; physiology
Calcium Channel Blockers - therapeutic use
Dihydropyridines - therapeutic use

Dihydropyridines - therapeutic use
Humans
Hypertension - drug therapy; physiopathology
Inflammation - drug therapy
Middle Aged
Neutrophils - drug effects; physiology

Associated Chemicals: Antihypertensive Agents (0) ; Calcium Channel Blockers (0) ; Dihydropyridines (0) ; lercanidipine (100427-26-7)

These are the highest related articles currently in the database:

See 100+ related articles.